Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-462P is a **pseudogene derived from the U6 small nuclear RNA (snRNA) gene**. U6 snRNA is a highly conserved non-coding RNA essential for spliceosome assembly and pre-mRNA splicing in eukaryotic cells[1][3]. The U6 snRNA genes are present in multiple copies in the human genome, and numerous pseudogenes have arisen from sequence duplication, such as RNU6-462P[3]. Pseudogenes like RNU6-462P are typically nonfunctional, do not code for active RNA or protein, and are not considered conventional therapeutic targets[3][5]. While some pseudogenes have acquired regulatory functions (such as acting as competitive endogenous RNAs or affecting parental gene expression), there is currently no specific evidence for RNU6-462P functioning in this way[2]. RNU6-462P does not have known disease associations, is not targeted by drugs, and is not used as a biomarker or implicated in safety concern contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 462, pseudogene (RNU6-462P).